CD274 and cancer: This ongoing, phase 1a/b, multicenter, dose escalation and expansion study enrolled patients with histologically or cytologically confirmed advanced cancer having ECOG PS 0-1, measurable disease (assessable by RECIST v1.1), and no prior treatment with PD-1/PD-L1 agents.